PMID- 26034370
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20181113
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 21
IP  - 20
DP  - 2015 May 28
TI  - Proton pump inhibitors therapy vs H2 receptor antagonists therapy for upper 
      gastrointestinal bleeding after endoscopy: A meta-analysis.
PG  - 6341-51
LID - 10.3748/wjg.v21.i20.6341 [doi]
AB  - AIM: To compare the therapeutic effects of proton pump inhibitors vs H(2) receptor 
      antagonists for upper gastrointestinal bleeding in patients after successful 
      endoscopy. METHODS: We searched the Cochrane library, MEDLINE, EMBASE and PubMed 
      for randomized controlled trials until July 2014 for this study. The risk of bias 
      was evaluated by the Cochrane Collaboration's tool and all of the studies had 
      acceptable quality. The main outcomes included mortality, re-bleeding, received 
      surgery rate, blood transfusion units and hospital stay time. These outcomes were 
      estimated using odds ratios (OR) and mean difference with 95% confidence interval 
      (CI). RevMan 5.3.3 software and Stata 12.0 software were used for data analyses. 
      RESULTS: Ten randomized controlled trials involving 1283 patients were included 
      in this review; 678 subjects were in the proton pump inhibitors (PPI) group and 
      the remaining 605 subjects were in the H(2) receptor antagonists (H(2)RA) group. The 
      meta-analysis results revealed that after successful endoscopic therapy, compared 
      with H(2)RA, PPI therapy had statistically significantly decreased the recurrent 
      bleeding rate (OR = 0.36; 95%CI: 0.25-0.51) and receiving surgery rate (OR = 
      0.29; 95%CI: 0.09-0.96). There were no statistically significant differences in 
      mortality (OR = 0.46; 95%CI: 0.17-1.23). However, significant heterogeneity was 
      present in both the numbers of patients requiring blood transfusion after 
      treatment [weighted mean difference (WMD), -0.70 unit; 95%CI: -1.64 - 0.25] and 
      the time that patients remained hospitalized [WMD, -0.77 d; 95%CI: -1.87 - 0.34]. 
      The Begg's test (P = 0.283) and Egger's test (P = 0.339) demonstrated that there 
      was no publication bias in our meta-analysis. CONCLUSION: In patients with upper 
      gastrointestinal bleeding after successful endoscopic therapy, compared with 
      H(2)RA, PPI may be a more effective therapy.
FAU - Zhang, Ying-Shi
AU  - Zhang YS
AD  - Ying-Shi Zhang, Qing Li, Bo-Sai He, Ran Liu, School of Pharmacy, Shenyang 
      Pharmaceutical University, Shenyang 110016, Liaoning Province, China.
FAU - Li, Qing
AU  - Li Q
AD  - Ying-Shi Zhang, Qing Li, Bo-Sai He, Ran Liu, School of Pharmacy, Shenyang 
      Pharmaceutical University, Shenyang 110016, Liaoning Province, China.
FAU - He, Bo-Sai
AU  - He BS
AD  - Ying-Shi Zhang, Qing Li, Bo-Sai He, Ran Liu, School of Pharmacy, Shenyang 
      Pharmaceutical University, Shenyang 110016, Liaoning Province, China.
FAU - Liu, Ran
AU  - Liu R
AD  - Ying-Shi Zhang, Qing Li, Bo-Sai He, Ran Liu, School of Pharmacy, Shenyang 
      Pharmaceutical University, Shenyang 110016, Liaoning Province, China.
FAU - Li, Zuo-Jing
AU  - Li ZJ
AD  - Ying-Shi Zhang, Qing Li, Bo-Sai He, Ran Liu, School of Pharmacy, Shenyang 
      Pharmaceutical University, Shenyang 110016, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Hemostatics)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Chi-Square Distribution
MH  - Endoscopy, Gastrointestinal/*adverse effects
MH  - Female
MH  - Gastrointestinal Hemorrhage/diagnosis/*drug therapy/etiology
MH  - Hemostatics/adverse effects/*therapeutic use
MH  - Histamine H2 Antagonists/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Patient Selection
MH  - Proton Pump Inhibitors/adverse effects/*therapeutic use
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC4445112
OTO - NOTNLM
OT  - H2 receptor antagonist
OT  - Meta-analysis
OT  - Proton pump inhibitor
OT  - Randomized controlled trial
OT  - Upper gastrointestinal bleeding
EDAT- 2015/06/03 06:00
MHDA- 2016/01/27 06:00
PMCR- 2015/05/28
CRDT- 2015/06/03 06:00
PHST- 2014/08/12 00:00 [received]
PHST- 2014/09/23 00:00 [revised]
PHST- 2014/11/07 00:00 [accepted]
PHST- 2015/06/03 06:00 [entrez]
PHST- 2015/06/03 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
PHST- 2015/05/28 00:00 [pmc-release]
AID - 10.3748/wjg.v21.i20.6341 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2015 May 28;21(20):6341-51. doi: 10.3748/wjg.v21.i20.6341.